Ligand Pharma (LGND) Tops Q1 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $312.85 +1.90%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.97, $0.30 better than the analyst estimate of $0.67. Revenue for the quarter came in at $29.6 million versus the consensus estimate of $26.45 million.
GUIDANCE:
Ligand Pharma sees FY2016 EPS of $3.41-$3.46, versus the consensus of $3.37. Ligand Pharma sees FY2016 revenue of $115-119 million, versus the consensus of $118.5 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Xometry, Inc. (XMTR) Tops Q3 EPS by 9c ; Offers Guidance
- Knife River Corporation (KNF) Misses Q3 EPS by 78c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
